FibroBiologics Announces Early Lease Termination and Office Consolidation

On April 3, 2026, FibroBiologics, Inc. entered into a Sublease Buyout Agreement with United Fire & Casualty Co. to terminate its sublease for premises in Webster, Texas. The termination was effective April 2, 2026, roughly 18 months ahead of the original expiration date of November 30, 2027. Under the terms of the agreement, the company settled its remaining rent obligations with a single payment of $45,108.25. FibroBiologics expects this early termination to result in approximately $0.8 million in future rent savings. This move is part of a strategic consolidation following the 2025 opening of the company's new 10,000-square-foot laboratory and office facility in Houston, Texas. By eliminating redundant office space and costs, the company aims to improve operational efficiency and focus resources on its fibroblast-based therapeutic programs. Consequently, the company has relocated its principal executive offices to 9350 Kirby Drive, Suite 300, Houston, Texas 77054.